For instance, treatment with DNA methylation inhibitors like 5-azacytidine or decitabine could reveal whether the observed hypomethylation patterns of PRKN or OPTN in kidney renal clear cell carcinoma and other cancers are reversible and whether they influence immune cell infiltration or tumor progression. This evidence concerns the gene PRKN and neoplasm.